Stockscreener 앱 받기
11.15
4.38%
-0.5011
전일 마감가:
$11.65
열려 있는:
$11.48
하루 거래량:
29,315
Relative Volume:
0.63
시가총액:
$1.92B
수익:
$549.97M
순이익/손실:
$458.86M
주가수익비율:
4.2495
EPS:
2.6236
순현금흐름:
$-89.06M
1주 성능:
+3.53%
1개월 성능:
+2.48%
6개월 성능:
-24.01%
1년 성능:
-27.76%
1일 변동 폭
$11.10
$11.49
1주일 범위
$10.75
$11.81
52주 변동 폭
$9.77
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
명칭
Hutchmed China Limited Adr
전화
-
주소
-
Compare HCM vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
11.16 | 1.97B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
16.98 | 52.99B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.815 | 43.25B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.71 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 31.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
560.07 | 23.60B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-11-24 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-05-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-03 | 개시 | Jefferies | Buy |
| 2020-10-02 | 개시 | Deutsche Bank | Buy |
| 2020-03-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 개시 | Goldman | Buy |
| 2019-11-19 | 개시 | CLSA | Buy |
| 2019-10-23 | 재확인 | BofA/Merrill | Buy |
| 2019-07-05 | 개시 | Macquarie | Outperform |
모두보기
Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
REGHutchmed China LtdAnnouncement on blocklisting six monthly return - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - AD HOC NEWS
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewswire Inc.
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in - GlobeNewswire
HUTCHMED (Nasdaq: HCM) files AIM block for 43,616,756 shares - Stock Titan
HCMHUTCHMED (China) Limited ADR Stock Price and Quote - Finviz
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewswire
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
Hutchmed China Limited Adr (HCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
1.62%
자본화:
|
볼륨(24시간):